Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)
Public ClinicalTrials.gov record NCT00652184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older
Study identification
- NCT ID
- NCT00652184
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- aRigen Pharmaceuticals, Inc.
- Industry
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- ARYS-01 (sorivudine) cream 3% or placebo cream Drug
- placebo Drug
- valaciclovir Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2008
- Primary completion
- May 31, 2009
- Completion
- Aug 31, 2009
- Last update posted
- Oct 6, 2008
2008 – 2009
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ARYS-0701 Site 3 | Beverly Hills | California | 90211 | — |
| ARYS-0701 Site 6 | Encino | California | 91436 | — |
| ARYS-0701 Site 7 | Vista | California | 92083 | — |
| ARYS-0701 Site 8 | Henderson | Nevada | 89014 | — |
| ARYS-0701 Site 9 | Las Vegas | Nevada | 89106 | — |
| ARYS-0701 Site 10 | New York | New York | 10003 | — |
| ARYS-0701 Site 11 | New York | New York | 10029 | — |
| ARYS-0701 Site 4 | New York | New York | 10032 | — |
| ARYS-0701 Site 12 | Raleigh | North Carolina | 27612 | — |
| ARYS-0701 Site 1 | Houston | Texas | 77058 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00652184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2008 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00652184 live on ClinicalTrials.gov.